Released Nov 15, 2021, before the open
10-Q filed Nov 15, 2021, 46 days after period end · 0001558370-21-015862
Q3 2021 · 10-Q
Revenue$12.05M$12.05M +11.7% vs Q3 2020+87.6% vs Q2 2021
Net Income-$4.20M-$4.20M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.09-$0.09 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$1,885,000N/M
Operating Cash Flowderived-$1,880,000N/M
Free Cash Flowderived-$2,224,000N/M
Margins · derived
Operating margin-15.6%+8.3 pt vs Q3 2020
Net margin-34.8%+6.3 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $12.05M | $10.79M | $14.25M | $663.00K |
| Net Income | -$4.20M | -$4.44M | -$3.56M | -$5.32M |
| EPS Diluted | -$0.09 | -$0.14 | -$0.24 | -$0.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR